Belite Bio Inc. reports nine-month 2025 general and administrative expenses of USD 25.4 million, up over 3 times
I'm PortAI, I can summarize articles.
Belite Bio Inc. reported a net loss of USD 52.3 million for the nine months ending September 30, 2025, compared to USD 26.0 million the previous year. Operating expenses were USD 56.1 million, with USD 30.8 million in R&D and USD 25.4 million in general and administrative expenses. The company had USD 157.0 million in cash and equivalents, USD 118.6 million in short-term investments, and a working capital of USD 269.1 million. The accumulated deficit was USD 159.9 million, with a net loss per share of USD 1.60.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments